Shares of Allergan surged more than 30% in early trading on Tuesday after AbbVie agreed to acquire the drugmaker for $63 billion. AbbVie’s bid of $188 a share in cash and stock represents a 45% premium from Allergan’s closing price on Monday. The acquisition will give AbbVie access to Allergan’s portfolio of profitable beauty drugs, including Botox. Watch Allergan trade live.
Botox-maker Allergan jumped as much as 30% before the opening bell